Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3919616 | 0.80 | TSHR (0.39) | TSHRNPSR1GLO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3919618 | 0.80 | TSHR (0.39) | TSHRNPSR1GLO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3930383 | 0.76 | GLO1 (0.37) | TSHRNPSR1GLO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3930385 | 0.76 | GLO1 (0.37) | TSHRNPSR1GLO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1245485 | 0.75 | ALDH1A1 (0.44) | TSHRNPSR1GLO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL17960733 | 0.75 | ALDH1A1 (0.44) | TSHRNPSR1GLO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4174829 | 0.74 | MAPT (0.44) | TSHRNPSR1GLO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5322687 | 0.72 | TSHR (0.41) | TSHRALDH1A1SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL44777 | 0.71 | — | — | |
| SCHEMBL10887615 | 0.70 | CYP3A4 (0.39) | TSHRNPSR1ALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10442792-B2 | Synthetic route to anti-viral agents | ABBVIE INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190084966-A1 | SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS | ABBVIE INC. | 2019-03-21 | — | — | US | disclosed |
| EP-3087085-B1 | SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE | GILEAD SCIENCES INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-10030033-B2 | Synthesis of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030033-B2 | Synthesis of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180057482-A1 | SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS | ABBVIE INC. | 2018-03-01 | — | — | US | disclosed |
| US-20180057482-A1 | SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS | ABBVIE INC. | 2018-03-01 | — | — | US | disclosed |
| US-9862728-B2 | Crystalline forms of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9809576-B1 | Synthetic route to anti-viral agents | ABBVIE INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809576-B1 | Synthetic route to anti-viral agents | ABBVIE INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9562058-B2 | Crystalline forms of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562058-B2 | Crystalline forms of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9440991-B2 | Synthesis of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440991-B2 | Synthesis of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| WO-2015100144-A1 | CRYSTALLINE FORMS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE | GILEAD SCIENCES, INC. (US) | 2015-07-02 | — | — | WO | disclosed |
| WO-2015100145-A1 | SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE | GILEAD SCIENCES, INC. (US) | 2015-07-02 | — | — | WO | disclosed |
| US-20150175625-A1 | CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175625-A1 | CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175626-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175626-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175625-A1 | CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND | HAVCR2, IFNAR1, ZC3HAV1 | TSHR 532/4885NPSR1 4042/4885GLO1 3827/4885 |
| US-10442792-B2 | Synthetic route to anti-viral agents | ACE, ACE2, PREP | TSHR 4664/4885NPSR1 3124/4885GLO1 2512/4885 |
| US-10030033-B2 | Synthesis of an antiviral compound | EIF2AK2, MAVS, SARS1 | TSHR 4561/4885NPSR1 3271/4885GLO1 2907/4885 |
| US-20180057482-A1 | SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS | ACE, ACE2, PREP | TSHR 4664/4885NPSR1 3124/4885GLO1 2512/4885 |
| US-20190084966-A1 | SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS | ACE, ACE2, PREP | TSHR 4664/4885NPSR1 3124/4885GLO1 2512/4885 |
| US-20150175626-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | EIF2AK2, MAVS, SARS1 | TSHR 4561/4885NPSR1 3271/4885GLO1 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.